Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2HSA in Type 2 Diabetes Mellitus – Phase II Multiple-Dose Study
CTR20200585Phase 2Completed
- Sponsor
- Zhejiang Huayang Pharmaceutical
- Start
- Apr 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of exenatide-human serum albumin fusion protein in type 2 diabetes mellitus (T2DM), sponsored by Zhejiang Huayang Pharmaceutical. Started Apr 2020; status: completed.
02
Drugs
exenatide-human serum albumin fusion protein
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20200585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200585.